Study of 387 lupus nephritis pts found pulmonary HTN in 15%. An increased risk of PH was seen w/ eGFR <30, and w/ low Hgb, low triglycerides. PH was independently associated with a higher risk (HR ~ 2.0) of all-cause mortality and adverse renal outcomes https://t.co/hdLjOZc9TI https://t.co/60lhdo93lm

Planetary Health in Rheumatology Dr. Antoni Chan interviews Dr. Nelly Ziade about her session Planetary Health, presented at Eular 2024 in Vienna, Austria. https://t.co/gBkwyO1dWQ https://t.co/VvGqwi6tlJ

Study of 2,974 SLE pts taking hydroxychloroquine (HCQ) found 584 w/ ≥1 hospitalization for SLE. Taking Lower doses of HCQ (≤5 mg/kg/d) or <400 mg/d were assoc w/ increased hospitalizations for active SLE (adjusted OR 4.20 & aOR 3.39, respectively) https://t.co/xXLiGFoU3L https://t.co/Sy36aOG81Y

Abatacept Misses on Shingrix Response Dr. David Liew discusses abstract POS0620 at Eular 2024 in Vienna, Austria. https://t.co/rNOARWzEcI https://t.co/xebXgsouta

Top 10 Drug companies (revenue) 10 Regeneron $12.2b 9 Vertex $8.9b 8 Amgen $26.3b 7 Gilead $27.3b 6 Lilly $28.5b 5 BMS $46.2b 4 Merck $59.3b 3 AbbVie $58.1b 2 J&J $94.9b 1 Pfizer $100.3b https://t.co/GNlGToGcb1 https://t.co/OWyVUBzeO6

JAMA: 3 prospective cohort studies in USA show that multivitamin use by 390 124 healthy adults did not alter mortality risk (HR, 1.04; 95% CI, 1.02-1.07) https://t.co/VDxrI5Bskw https://t.co/o9wdITR0UT

Is Rheumatoid Arthritis Preventable? Many conventional synthetic, biological, biosimilar, and targeted synthetic disease-modifying anti-rheumatic drugs are currently commercially available for the effective treatment of rheumatoid arthritis. https://t.co/KmAFGwx414 https://t.co/ag5W9j9Kky

FDA has approved risankizumab (Skyrizi) to treat adults with moderately to severely active ulcerative colitis (UC), making it the IL-23 inhibitor approved for UC. Approval is based on two large phase 3 clinical trials (COMMAND, INSPIRE) https://t.co/JWX5SBEvT5 https://t.co/MrMFmOyQqa

JAK inhibitors have been used as adjunctive therapy to reduce flammation arising with checkpoint inhibitor use in cancer (Hodgkins, Lung CA), using itacitinib w/ pembrolizumab or ruxolitinib & nivolumab improved trial outcomes https://t.co/hMmrifhiNN https://t.co/LPHc5GyOaA

PsA: Switch or Cycle, the Eternal Question Dr. Aurelie Najm reports on abstracts POS0278 and POS0266 presented at Eular 2024 in Vienna, Austria https://t.co/fBtoTQy5Wx https://t.co/rbvaqy0oyC

Artificial Intelligence: Detection of CPPD on Hand Radiographs Dr. Antoni Chan interviews Dr. Thomas Hugle about abstract OP0112 presented at Eular 2024 in Vienna, Austria. https://t.co/jQrwKXuaDc https://t.co/Ecv69wvHxA